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A misinterpretation of the results from ONTARGET (Ongoing
Telmisartan alone and in combination with ramipril Global
Endpoint Trial) has sparked both efficacy and safety concerns
within the nephrology community regarding the utilization
of dual RAAS blockade to achieve more desirable renal
outcomes. Two important considerations are requisite prior
to interpreting these results, specifically: the context of the
cohort studied (non-proteinuric CKD patients at low risk of
progression) and the inadequate power of the study to
assess renal outcomes. The cardiac and renal protection
afforded from dual RAAS blockade in select populations,
particularly proteinuric CKD and CHF, is supported by
literature. Moreover, the response to dual RAAS blockade
involving different combinations of ACE inhibitors,
angiotensin receptor blockers, mineralocorticoid receptor
antagonists, and direct renin inhibitors, may not be uniform
amongst all patient populations. Will we continue to
withhold the appropriate medical therapy from certain
individuals based on misconstrued data? The proceedings
provide a critical analysis of the ONTARGET study and an
evidence-based substantiation for the utilization of various
forms of dual RAAS blockade in proteinuric kidney disease
and beyond.
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ONTARGET
A critical appraisal of the ONTARGET (Ongoing Telmisartan
alone and in combination with ramipril Global Endpoint
Trial) trial yields information that undermines the power and
applicability of the study results. The ONTARGET study was
conducted in predominantly non-proteinuric individuals
(mean urinary albumin/creatinine ratio of 7.2mg/g) with
preserved renal function (mean estimated glomerular filtra-
tion rate (eGFR) of 73.6ml/min per 1.73m2) at low risk of
chronic kidney disease (CDK) progression (sustained rate of
GFR decline was 1ml/min/year).1 The proportion of diabetic
and hypertensive patients in this study trial was small for a
renal outcome trial, 36.7–38.0% and 68.5–69%, respectively.1
Historically, major renal outcome trials that make firm
conclusions regarding progression of CDK examine high-risk
populations with an eGFR o60ml/min and/or macroalbu-
minuria.
The following information regarding hemodialysis in
ONTARGET should be considered: the need for hemodialysis
was determined arbitrarily and the data on hemodialysis
events was collected through questionnaires. The results of
ONTARGET may be influenced by either the lack of
calibration for serum creatinine measurements, and/or the
lack of a uniform assay technique. Confirmatory testing of
‘doubling of serum creatinine’ was not carried out, as is
standard in major renal outcome trials. Lastly, the appro-
priate adjustments for the wide fluctuations in urinary
albumin/creatinine ratios were not carried out.
ONTARGET lacked the power to detect differences in
renal outcomes. As expected from the low levels of
albuminuria, death was the main component of the
composite end point that drove the primary renal outcome
(84% of all the events).1 A secondary end point of dialysis
and doubling of creatinine was similar with telmisartan
(n¼ 189) and ramipril (n¼ 174), and more frequent with
combination therapy (n¼ 212, P¼ 0.038 versus ramipril, but
P¼NS versus telmisartan).1 It should be noted that 3 of the
165 reported cases of hemodialysis were later retracted, in
addition to 3 additional cases in which hemodialysis
information could not be obtained. The analysis counted
total dialysis (acute and chronic), and thus is not reflective of
how events are accumulated in CDK treatment trials. The
removal of acute hemodialysis from the renal end points led
to insignificant differences between the three groups, in
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regards to achieving secondary outcomes. The proportion of
patients that required chronic hemodialysis was very low
(0.36–0.40%), and varied little between the various treatment
arms.1
As anticipated, the initial eGFR decline from baseline to 6
weeks was significantly greater with dual renin–angiotensin–
aldosterone system (RAAS) blockade. The reduction in the
eGFR from dual RAAS blockade is a manifestation of reduced
intraglomerular pressure and is generally considered a
marker of effective RAAS blockade.2,3 The sustained decline
in eGFR (ml/min/year) from 6 weeks to 56 months (4.7
years) was 0.27 (ramipril), 0.44 (telmisartan), and 0.53
(combination).1 These sustained reductions in eGFR are
actually below the expected, age-related decline in renal
function (0.6–1.1ml/min/year).4 Although the decrement in
renal function observed in the dual RAAS blockade arm of
ONTARGET was slightly more than the control arm, this
would not be considered a major loss of kidney function and,
more importantly, is unlikely to correlate with untoward
renal outcomes.
In contrast to previous treatment trials using RAAS
blockade that showed reduction in proteinuria over time, all
groups showed increases in urinary albumin/creatinine ratio
over time (31% ramipril, 24% telmisartan, and 21%
combination).1 The observed increase in albuminuria over
time among all treatment arms may be a reflection of either
an inability to achieve adequate RAAS blockade or a reduced
renoprotective benefit from combination therapy at lower
ranges of albuminuria. The progression to macroalbuminur-
ia, which is considered a better measure of renoprotection
than overall reduction of proteinuria, was decreased
more significantly in the combination group than with
monotherapy.5
Renal abnormalities were reported in 871 (10.2%)
participants assigned to ramipril, 906 (10.6%) assigned to
telmisartan, and 1148 (13.5%) assigned to combination
therapy (relative risk (RR) 1.33, 95% confidence interval (CI)
1.22–1.44, Po0.0001 for combination therapy versus rami-
pril), and as a reason for permanently stopping medication in
60 (0.7%) of participants assigned to ramipril, 68 (0.8%)
assigned to telmisartan, and 94 (1.1%) assigned to combina-
tion therapy (RR 1.58, Po0.0050 for combination therapy
versus ramipril).5 The substantial dropout rate in the
combination therapy group compared with the monotherapy
group (406 patients on combination therapy, 149 patients on
ramipril alone, 229 on telmisartan alone) may have resulted
in bias between the study groups in the participants that
remained.1 Applying intention-to-treat analysis, in the
setting of differential dropout rates, can inadvertently lead
to further bias and may have weighed unfavorably for the
combination group.6
Although the number of patients who had an increase in
the potassium level of more than 5.5mmol/l was higher in
the combination group (283 patients in ramipril group, 287
patients in telmisartan group, and 480 patients in combina-
tion group, Po0.001 for comparison between combination
and ramipril group), only two patients required acute
hemodialysis for hyperkalemia in the combination group.1,5
Also, as stated previously, the risk of end-stage renal disease
was similar between combination and monotherapy groups,
despite the slightly higher incidence of acute hemodialysis in
the combination group. Thus, the absolute risk rather than
the RR of adverse ‘renal’ events is minimal and should not
obviate the use of dual RAAS blockade.
Echoing the statement by Parving et al.,9 ‘the ONTARGET
study, which investigated dual RAAS blockade in a popula-
tion at low risk for CKD progression, applying insufficiently
measured renal endpoints, confounded by death and acute
hemodialysis, has resulted in inconclusive evidence and
misinterpretation of the role of dual RAAS blockade and the
importance of albuminuria as a valid surrogate end point for
renal disease’.
SAFETY
ONTARGET participants on dual RAAS blockade had a
higher incidence of serum potassium45.5mmol/l compared
with patients on telmisartan or ramipril monotherapy (5.6%
versus 3.4% versus 3.3%, respectively).1 This excess hyperka-
lemia may partially be explained by the low prevalence of
diuretic use—with resultant kaliuresis—in the various
treatment groups (27.6–28.6%).1 Furthermore, a retrospec-
tive review of hyperkalemia associated with dual RAAS
blockade found little evidence that potassium levels
45.5mmol/l were associated with adverse events.8 The key
message from ONTARGET should be that despite an
increased risk of serum potassium elevations with dual
RAAS inhibition, the absolute incidence remains low, and
patients with risk factors predisposing to hyperkalemia
should have serum electrolytes monitored periodically.
ONTARGETalso raised concerns that dual RAAS blockade
may hasten CKD progression. It is important to realize that
the ONTARGET renal subanalysis was not powered to
evaluate renal outcomes; indeed, of the nearly 3500
individual composite end point events, only 600 were
specifically renal, and death from any cause was the key
driver of the result. A well-conducted, prospective trial in
patients with advanced, proteinuric CKD is still necessary to
definitely determine the efficacy of combination RAAS
blockade on CKD progression. ALTITUDE (Aliskiren Trial in
Type 2 Diabetes Using Cardio-Renal Endpoints) and Combi-
nation Angiotensin Receptor Blocker and Angiotensin-
Converting enzyme inhibitor for treatment of diabetic
nephropathy (VA NEPHRON-D) are two ongoing trials
examining the long-term, renal effects of dual RAAS blockade
in diabetic nephropathy.9,10
THE VALUE OF PROTEINURIA AND RAAS BLOCKADE IN
PROTEINURIC KIDNEY DISEASE
Numerous studies have shown that treating patients with
diabetic/non-diabetic CKD and clinical albuminuria with an
angiotensin-converting enzyme (ACE) inhibitor or angioten-
sin receptor blocker (ARB) reduces proteinuria and slows
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progression of CKD, and that the greater the diminution in
proteinuria, the greater the benefit. A post-hoc analysis of
RENAAL (Reduction in End Points in Noninsulin-dependent
Diabetes Mellitus with the Angiotensin II Antagonist
Losartan) revealed that the anti-proteinuric effect of losartan
conferred renoprotective benefits that exceeded the benefit of
blood pressure control alone in diabetic nephropathy
patients11 (see Figure 1).
In addition to predicting CKD progression, clinical
albuminuria or proteinuria, is a well-established risk marker
for cardiovascular disease. Reduction in albuminuria confers
significant reduction in cardiovascular events. Post-hoc
analysis of the RENAAL database showed that albuminuria
is the most important factor in predicting the cardiovascular
risk in patients with type 2 diabetic nephropathy.12 This
study showed that at the initial 6-month period, albuminuria
reduction was the only predictor for cardiovascular outcomes
among the risk factors measured.12 The cardiovascular
outcomes at 6 months included: an 18% reduction in
cardiovascular risk for every 50% reduction in albuminuria,
and a 27% reduction in heart failure risk for every 50%
reduction in albuminuria.12
Does proteinuria reduction equate with improved renal
outcomes and patient survival in a CKD patient population?
Post-hoc analyses of data from Heart Outcomes Prevention
Evaluation, Losartan Intervention for Endpoint Reduction,
RENAAL, Irbesartan Diabetic Nephrology Trial, and African-
American Study of Kidney Disease and Hypertension studies
have shown clearly that a reduction in clinical albuminuria
or proteinuria correlated with a decrease in the risk of
composite end points, including death.13–17 More convincingly,
these reductions in composite end points occur independently
of reductions in blood pressure. In a post-hoc analysis of
Irbesartan Diabetic Nephrology Trial, for each halving of
proteinuria level between baseline and 12 months with
irbesartan, risk for kidney failure was reduced by more than
half (hazard ratio, 0.44; 95% CI, 0.40–0.49; Po0.001).18 It is
certain that proteinuria remains a useful predictive tool for
incident cardiovascular, renal, and mortality events, and can be
used as a surrogate for RAAS blockade treatment efficacy.
PROTEINURIC KIDNEY DISEASE AND DUAL RAAS BLOCKADE
When examining the impact of dual RAAS blockade on CKD
progression in proteinuric kidney disease, it is important to
realize that the time interval required to manifest the
renoprotective effects of blood pressure reduction alone is
dependent on the baseline level of albuminuria, as eloquently
described by Peterson et al.19 (see Figure 2). The renal benefit
of dual RAAS blockade in kidney disease patients with
minimal proteinuria, similar to the ONTARGET study
population, may be delayed by more than 36 months and
extended follow-up is needed to determine the true impact of
combined therapy in this population. Most studies evaluating
the renoprotective effects of dual RAAS blockade are too
short to make accurate determinations regarding long-term
renal protection.
Is dual RAAS blockade with ACE inhibitor/ARB combina-
tion superior to monotherapy for reduction of proteinuria? A
recent meta-analysis involving individuals with and without
diabetes and with microalbuminuria or proteinuria deter-
mined that the reduction in proteinuria associated with
combined ACE inhibitor and ARB therapy was more
significant than either drug alone.20 In this meta-analysis,
five of the seven trials (71.4%) comparing combination
therapy versus single agent (ACE inhibitor or ARB) favored
treatment with combination therapy given the primary end
point of reduction in proteinuria at 5–12 months (ratio of
means 0.48–0.76).20 Only two of the seven trials (28.6%)
examined showed increases or no change in the degree of
proteinuria during the 5–12-month period.20 Interestingly,
one of the two trials associated with negligible or increased
proteinuria over the study period was carried out in type 2
diabetic patients with hypertension and microalbuminuria,
similar to the profile of the ONTARGET participants.21 In
total, combination therapy reduced proteinuria by 20–25%
more than either drug alone.20
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Figure 1 |Kaplan–Meier curves for renal end points and end-stage renal disease (ESRD) stratified by albuminuria in patients with
type 2 diabetic nephropathy. The high (X3.0 g/g) as well as the intermediate (X1.5o3.0 g/g) albuminuria groups show significantly more
renal events (doubling serum creatinine, ESRD, and/or death) and ESRD than the low (o1.5 g/g) albuminuria group over a 48-month
interval.11
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Most of the short-term blood pressure studies have shown
an additional drop in systolic and diastolic pressure when an
ARB was added to an ACE inhibitor and vice versa, regardless
of the dose level of the first drug. Although the blood
pressure lowering effect of dual RAAS blockade is modest
compared with the combination of a single RAAS blocker
and calcium-channel blockers or diuretics; studies show that
the antiproteinuric effects of dual RAAS blockade may occur
independently of blood pressure control.22–24 As will be
discussed later, the AVOID (Aliskiren in the Evaluation of
Proteinuria in Diabetes) trial showed that the addition of
aliskiren to losartan in type 2 diabetic nephropathy patients
reduced the mean albumin-to-creatinine ratio by 20%,
despite no statistically significant change in blood pressure.22
In summary, the characteristics of RAAS blocking agents,
either alone or in combination, may confer additional,
pleiotropic effects that transcend the renal and cardiac benefit
anticipated from blood pressure control alone.
Why does dual RAAS blockade confer an additive
renoprotective effect in patients with diabetic nephropathy?
Recently, Park et al.25 identified ‘non-ACE’ pathways
responsible for the majority of angiotensin II production in
the type 2 diabetic leptin receptor-deficient mouse kidney.
Inhibition of these ‘non-ACE’ enzymes abolished the afferent
arteriole response to intrarenal conversion of angiotensin I to
angiotensin II in the diabetic kidney, but not the control
kidney.25 These studies provide a plausible explanation for
the superior effects of combining an ACE inhibitor with an
angiotensin1 receptor antagonist relative to ACE inhibitor
therapy alone to provide additional protection from diabetic
nephropathy in humans.
CONGESTIVE HEART FAILURE
ACE inhibitor/ARB combination
There is convincing evidence that dual RAAS blockade with
ACE inhibitor and ARB is valuable in reducing cardiovas-
cular events in select populations. The CHARM-Added
(Candesartan in Heart Failure Assessment of Morbidity and
Mortality) study evaluated individuals with New York Heart
Association functional class II–IV congestive heart failure
(CHF) and left-ventricular ejection fractionp40%, and who
were being treated with ACE inhibitors. The addition of
candesartan to ACE inhibition resulted in significant
reductions in each of the primary outcomes, which included
cardiovascular death and hospital admission for CHF (483
(38%) patients in the candesartan group and 538 (42%) in
the placebo group experienced the primary outcome
(unadjusted hazard ratio 0.85 (95% CI 0.75–0.96),
P¼ 0.011; covariate adjusted P¼ 0.010)).26 Similarly, Hamr-
off et al.27 found that the addition of losartan enhances peak
exercise capacity, alleviates symptoms, and improves New
York Heart Association classification in patients with CHF
who are severely symptomatic despite treatment with
maximally recommended or tolerated doses of ACE inhibitors.
ACE inhibitor/aldosterone receptor antagonist combination
The RALES (Randomized Aldosterone Evaluation Study)
investigated the role of spironolactone in treating individuals
with New York Heart Association class IV heart failure and
depressed left ventricular function (ejection fractionp35%).
It may be noted that 95% of the individuals in this study were
on ACE inhibition during the study period. The addition
of low dose spironolactone conferred significant reduction
(by about 30% RR) in death and hospitalizations among
treated patients.28 The median creatinine concentration in
the spironolactone group increased by approximately
0.05–0.10mg/dl and the median potassium concentration
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Figure 2 | Estimated mean decline in glomerular filtration rate
(GFR) from baseline to selected follow-up times in individuals
with chronic kidney disease. The usual (dashed line) and low
(solid line) blood pressure groups are compared. The time
relationship between baseline proteinuria and decline in GFR with
standard and low blood pressure interventions is illustrated.
Individuals with the highest degree of albuminuria (X3 g/g)
experienced stabilization in GFR with blood pressure control at
3–4 months. Individuals with moderate albuminuria experienced
stabilization in GFR with blood pressure control at B24 months.
Individuals with low albuminuria (0.25–1 g/g) experienced
stabilization of GFR at 24–32 months. Individuals with the lowest
levels of albuminuria (p0.25 g/g) do not experience GFR
stabilization during the study period of 36 months.19 B¼baseline
visit before randomization, F¼ follow-up visits at each given
month. Usual blood pressure (dashed line) target mean arterial
pressure p107mmHg for patients p60 years old and
p113mmHg for patients 460 years old. Low blood pressure
(solid line) target mean arterial pressure p92mmHg for patients
p60 years old and p98 for patients 460 years old.
542 Kidney International (2010) 78, 539–545
min i rev iew MR Lattanzio and MR Weir: Dual RAAS blockade is desirable in kidney disease: PRO
increased by 0.30mmol/l, neither adverse event that would be
considered clinically significant.28 The EPHESUS (Eplere-
none Post-Acute Myocardial Infarction Heart Failure Efficacy
and Survival Study) studied the effect of eplerenone (a
selective aldosterone receptor blocker) combined with
optimal medical therapy (including ACE inhibitors and
ARBs) on morbidity and mortality among patients with
acute myocardial infarction complicated by left ventricular
dysfunction and heart failure.29 In the group treated with
eplerenone, 86% of the patients were receiving either ACE
inhibitors or ARB therapy as part of optimal medical
therapy.29 At 16 months follow-up, the eplerenone group
had a significant reduction in all-cause and cardiovascular
mortality (RR, 0.85; 95% CI, 0.75–0.96, P¼ 0.008 and RR,
0.83; 95% CI, 0.72–0.94, P¼ 0.005, respectively).29 In
addition, eplerenone use was associated with a reduction in
the rate of sudden death from cardiac causes. The benefits of
eplerenone plus optimal medical therapy, including ACE
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Figure 3 |Value of proteinuria reduction in proteinuria chronic kidney disease. (a, b) Kaplan–Meier curves for cardiovascular (composite
of myocardial infarction, stroke, first hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, or
cardiovascular death) and heart failure end points stratified by albuminuria in patients with type 2 diabetic nephropathy. The high (X3.0 g/
g) as well as the intermediate (X1.5o3.0 g/g) albuminuria groups show significantly more cardiovascular (CV) and heart failure events than
the low (o1.5 g/g) albuminuria group over a 48-month interval.12 (c, d) Hazard ratio for CV and heart failure end points as functions of
baseline albuminuria in patients with type 2 diabetic nephropathy. (Relation is corrected for baseline risk marker.) The highest levels of
albuminuria relative to lowest level correlates with the highest hazard ratio of achieving cardiovascular and heart failure end points.12
(e) The clinical implications of antiproteinuric therapy.
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inhibitors and ARBs, was associated with only a small
increase serum potassium in the treatment group.29
Proteinuria and CHF
It is evident that proteinuria has tremendous predictive value
in CHF, both as a marker of future events and as a
therapeutic target. Patients with diabetic nephropathy and
albuminuria greater than 3 g/g have a 2.7-fold higher risk for
CHF when compared with patients with low albuminuria
(o1.5 g/g).12 In a post-hoc analysis of RENAAL, every 50%
reduction in albuminuria resulted in a 27% reduction in CHF
risk among diabetic nephropathy patients.12 Moreover,
albuminuria was the strongest predictor of cardiovascular
outcomes, including hospitalization for CHF.12 (see Figure 3)
Extinguishing proteinuria by targeting different constituents
of the RAAS should be endorsed as a potential strategy to
reduce incident CHF events among high risk individuals.
BEYOND ACE INHIBITOR-ARB COMBINATIONS
Mineralocorticoid receptor antagonists and direct renin
inhibitors are gradually finding their niche within the
available armamentarium of RAAS-blocking agents. The
AVOID trial evaluated the renoprotective effects of dual
RAAS blockade in hypertensive individuals with diabetic
nephropathy. The addition of the direct renin inhibitor,
aliskiren, to losartan resulted in a 20% reduction in
albuminuria (95% CI, 9–30, Po0.001) with a reduction of
50% or more in 24.7% of the patients who received aliskiren
as compared with 12.5% of those who received placebo
(Po0.001).22 The reduction in proteinuria conferred by dual
RAAS blockade (aliskiren and losartan) occurred indepen-
dently of blood pressure-lowering effects. From a safety
perspective, dual RAAS blockade did not result in more
adverse events, including hyperkalemia, when compared with
the monotherapy group.
A recent study examined the antiproteinuric effects of
adding the mineralocorticoid receptor antagonist, spirono-
lactone, versus losartan to ACE inhibition (lisinopril 80mg
daily) in patients with diabetic nephropathy. Despite no
differences in blood pressures, albuminuria decreased more
in the spironolactone group than in the losartan group, when
compared with placebo (34 versus 16.8%).24 Similarly, the
coadministration of eplerenone with enalapril substantially
reduced albuminuria compared with enalapril alone in
patients with diabetes without significant increases in serum
potassium levels.30 Additional data suggest that adding
an mineralocorticoid receptor antagonist to ACE inhibitor
and/or ARB therapy yields significant decreases in proteinuria
without adverse effects of hyperkalemia and impaired renal
function.31
Mineralocorticoid receptor antagonists combined with
either ACE inhibitor or ARB have proven beneficial for blood
pressure control, reduction of albuminuria, and regression of
left ventricular hypertrophy. Krum et al.32 found that adding
eplerenone to either ACE inhibitor or ARB in individuals
with poorly controlled blood pressure resulted in improved
systolic blood pressure control. Moreover, adverse events
were generally not severe and did not significantly differ
between the eplerenone and placebo groups. The Effects for
Eplerenone, Enalapril and Eplerenone/enalapril in patients
with essential hypertension and left ventricular hypertrophy
(4E) study showed that the combination of eplerenone and
enalapril resulted in a greater reduction in left ventricular
mass, albuminuria, and blood pressure than monotherapy.33
Further clinical trials are necessary in this population to
confirm the long-term, beneficial effects of dual RAAS
blockade on renal outcomes.
CONCLUSION
The role of dual RAAS blockade to achieve valuable renal end
points seems promising in individuals with proteinuric CKD,
particularly diabetic nephropathy. In addition, the ability of
dual RAAS blockade to confer cardiac protection in
individuals with CHF has substantial implications. This is
evident in the literature whether looking at the ACE
inhibitor/ARB combination or a combination of these drugs
with a mineralocorticoid receptor antagonist or direct renin
inhibitor. These benefits will have to be balanced against the
slightly higher risk of hyperkalemia and tolerability concerns
with combination therapy. Reduction of albuminuria, in
conjunction with, or even independent of blood pressure,
may be the common thread that equates to better outcomes
in these select populations and should be considered an
invaluable measure of therapeutic success. The authors,
herein, discourage the indiscriminate refrain from dual RAAS
blocker use. Conversely, the application of dual RAAS
inhibition, in selected populations, should be championed
for its ability to accord cardiovascular and renal protection
beyond that achievable through monotherapy. It seems that
the time has come to rescue dual RAAS blockade from the
shadow cast by misconstrued data.
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